These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16697875)

  • 21. Treatment of high-risk, non-muscle-invasive bladder cancer.
    Lerner SP
    Nat Clin Pract Urol; 2006 Aug; 3(8):398-9. PubMed ID: 16902498
    [No Abstract]   [Full Text] [Related]  

  • 22. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.
    Parekh DJ; Bochner BH; Dalbagni G
    J Clin Oncol; 2006 Dec; 24(35):5519-27. PubMed ID: 17158537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival from bladder cancer in England and Wales up to 2001.
    Whelan P
    Br J Cancer; 2008 Sep; 99 Suppl 1(Suppl 1):S90-2. PubMed ID: 18813273
    [No Abstract]   [Full Text] [Related]  

  • 24. Re: Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer. D. Margel, R. Tal and J. Baniel. J Urol 2007; 178: 2297-2301.
    Suzuki K
    J Urol; 2008 Jun; 179(6):2481; author reply 2481. PubMed ID: 18436255
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Irani J
    Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invasive T1 bladder cancer: indications and rationale for radical cystectomy.
    Stein JP; Penson DF
    BJU Int; 2008 Aug; 102(3):270-5. PubMed ID: 18494831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Non-invasive molecular detection of bladder cancer].
    Hatachmi S
    Harefuah; 2009 Jan; 148(1):66-9, 86. PubMed ID: 19320394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunotherapy of invasive cancer of the urinary bladder].
    Kharchenko VP; Kaprin AD; Ivanov SA; Klimenko AA
    Vopr Onkol; 2006; 52(6):659-62. PubMed ID: 17338244
    [No Abstract]   [Full Text] [Related]  

  • 30. Muscle-invasive bladder tumour: can the bladder be preserved?
    Sella A
    BJU Int; 2008 Nov; 102(9):1053-4. PubMed ID: 18715247
    [No Abstract]   [Full Text] [Related]  

  • 31. Reducing bladder cancer deaths: the preemptive cystectomy approach.
    Konety BR
    Cancer; 2009 Mar; 115(5):914-7. PubMed ID: 19152439
    [No Abstract]   [Full Text] [Related]  

  • 32. Radical cystectomy with an extended pelvic lymphadenectomy: rationale and results.
    Mills RD; Fleischmann A; Studer UE
    Surg Oncol Clin N Am; 2007 Jan; 16(1):233-45. PubMed ID: 17336246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical evaluation of the prostate from cystoprostatectomies for bladder cancer: insights from a complete sampling with the whole mount technique.
    Montironi R; Cheng L; Mazzucchelli R; Scarpelli M; Kirkali Z; Montorsi F; Lopez-Beltran A
    Eur Urol; 2009 Jun; 55(6):1305-9. PubMed ID: 18995951
    [No Abstract]   [Full Text] [Related]  

  • 34. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer.
    Li M; Song T; Yin ZF; Na YQ
    Chin Med J (Engl); 2007 Mar; 120(6):469-73. PubMed ID: 17439739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: Platz CE, Cohen MB, Jones MP, Olson DB, Lynch CF. Is microstaging of early invasive bladder cancer of the urinary bladder possible or useful? Mod Pathol 1996;9:1035-9.
    Angulo JC; Lopez JI
    Mod Pathol; 1997 Aug; 10(8):854. PubMed ID: 9267831
    [No Abstract]   [Full Text] [Related]  

  • 36. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
    Hendricksen K; Witjes JA
    Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostatic transitional cell carcinoma: pathologic features and clinical management.
    Shen SS; Lerner SP
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1155-62. PubMed ID: 18028024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining optimal therapy for muscle invasive bladder cancer.
    Herr HW; Dotan Z; Donat SM; Bajorin DF
    J Urol; 2007 Feb; 177(2):437-43. PubMed ID: 17222605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival.
    Bellmunt J; Hautmann RE
    Eur Urol; 2008 Nov; 54(5):1192-7. PubMed ID: 18707804
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer.
    Bruins HM; Stein JP
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1091-101. PubMed ID: 18588454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.